FDA extends review period for Eisai's LEQEMBI subcutaneous injection
The U.S. Food and Drug Administration has extended the review period by three months for Eisai Co., Ltd. and Biogen ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)